This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Lung Disease Therapeutics Market

Lung disease diagnoses have increased as a result of increased awareness of new medical diagnostic equipment and improved treatments

Lung Disease Therapeutics Market by Disease Type, Treatment Type, Distribution Channel & Region - Forecast 2022 - 2032

Lung Disease Therapeutics Market Snapshot (2022-2032)

[280 Pages Report] The global lung disease therapeutics market garnered a market value of US$ 79,833.6 Million in 2022 and is expected to accumulate a market value of US$ 145,960.2 Million by registering a CAGR of 6.21% in the forecast period 2022-2032.

Growth of the lung disease therapeutics market can be attributed to increasing air pollution and the rising prevalence of COPD. The market for lung disease therapeutics registered a CAGR of 5.2% in the historical period 2016-2021.

Data Points

Key Statistics

Estimated Base Year Value (2021)

US$ 75,234.14 Million

Expected Market Value (2022)

US$ 79,833.6 Million

Anticipated Forecast Value (2032)

US$ 145,960.2 Million

Projected Growth Rate (2022-2032)

6.21% CAGR

Lungs are the complex human organ that brings in oxygen and expels carbon dioxide by expanding and relaxing continuously. Lung disease is one of the most common medical conditions globally. Lung disease is very severe and is highly responsible for increasing mortality around the globe. Lung disease lead to uneasiness and complications in respiration.

Some major lung diseases are COPD, asthma, bronchopulmonary dysplasia, and pulmonary fibrosis. Basically, there are two types of treatment for lung disease viz drug treatment and oxygen therapy. Drug treatment is most preferred by physicians as well as patients owing to its instant effect. Oxygen therapy is provided to COPD patients through ventilators and concentrators for long-term care.

Customize this Report

Let us know your requirement to get
100% FREE customization

Which Are Some Prominent Drivers Spearheading Lung Disease Therapeutics Market Growth?

Increasing Prevalence of Lung Diseases Drives the Growth of the Market

The rising prevalence of COPD and asthma are the primary factors driving the growth of lung disease therapeutics market. The change in lifestyle of people and increase in numbers of smokers globally will propel the growth of lung disease therapeutics market. Besides, rising geriatric population suffering from various lung disease will upsurge the growth of lung disease therapeutics market.

Furthermore, advancement in technology and increasing research and development leads to availability of more efficient drug therapeutics will boost the growth of lung disease therapeutics market.

The lung disease therapeutics market is expected to show exponential growth over the forecast period. The lung disease therapeutics market is classified on the basis of disease type, treatment type and distribution channel. By disease type, COPD segment is expected to dominate the market value of lung disease therapeutics market.

Drug treatment is expected to be the most lucrative segment for lung disease therapeutics market by treatment type. Among all distribution channels, retail pharmacies are expected to show faster growth than other segments.

What Are The Challenges Faced By The Lung Disease Therapeutics Industry?

The Cost Associated with the Treatment of Lung Diseases May Impede the Growth of the Market

Although the lung disease therapeutics market has numerous end-uses, there are numerous obstacles that likely pose a challenge to market growth. The high cost of drugs for the treatment of lung disease will restrain the growth of this market to some extent.

Some side effects after consumption of anti-inflammatory drugs will also hinder the growth of the lung disease therapeutics market. All these factors are expected to derail the progress of the lung disease therapeutics market.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Why Is North America Emerging As An Opportunistic Lung Disease Therapeutics Market?

Growing Prevalence of Lung Related Disorders to Boost the Growth of the Market

North America is expected to have the maximum market share of the lung disease therapeutics market due to the high number of people suffering from COPD and asthma in the U.S. After North America. In addition, technologically advanced healthcare facilities are contributing to the growth of the market.

Moreover, increasing awareness regarding early therapeutics for lung disease is contributing to the growth of the market. Thus, North America is expected to possess 35.0% market share in 2022.

In addition, with the advent of new treatment therapies such as targeted drug therapy, stereotactic are aiding the growth of lung disease therapeutics market. According to the American Lung Association, COPD is the third most common cause of death in the country.

How Is Europe Likely To Contribute To Lung Disease Therapeutics Market Growth?

Technological Advancement in Healthcare to Drive the Growth of the Market in the Region.

Rising healthcare infrastructure and favorable medical insurance are responsible for the high growth of the lung disease therapeutics market in Western Europe. Rising pollution and climate change in the European region will lead to the robust growth of the lung disease therapeutics market.

Moreover, government initiatives to spread awareness regarding regular lung check-ups is escalating the demand for lung disease therapeutics. Thus, Europe is expected to hold a 29.0% market share in 2022. The region's market is being driven by an increase in the prevalence of chronic disease and Asthma being the most common issue among children.

A number of technological advancements in respiratory diagnostic testing have paved the way for the market's expansion, including the use of artificial intelligence and the internet of things (IoT), among other things.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Will The Asia Pacific Emerge As An Attractive Lung Disease Therapeutics Market?

The High Prevalence of Lung Diseases among the Older Population Led to Increased Demand for Lung Diseases Therapeutics in Asia Pacific

The Asia Pacific is expected to remain at the forefront by generating the largest lung diseases therapeutics market share in the upcoming years. The presence of numerous leading companies in the region is anticipated to drive the regional market. The rising aging population prone to lung diseases across developing countries, such as India and China is likely to propel the demand for lung disease therapeutics in the Asia Pacific.

The high penetration rate of state-of-the-art devices and the presence of a well-established healthcare system across Asia Pacific are a couple of other factors that would foster the market. For instance, In August 2022- Sanofi and Innovent Biologics announced a collaboration to bring innovative medicines to patients in China with difficult-to-treat cancers.

Innovent is a leading biopharmaceutical company with strong clinical development capabilities and a broad commercial footprint in China.

Start-Ups For Lung Disease Therapeutics Market

Key start-up players in the lung disease therapeutics are Omnispirant, Atriva Therapeutics, Altavant Sciences, Exvastat and ReAlta Life Sciences.

  • Altavant Sciences, a key start-up in the lung disease therapeutics market is developing small molecule inhibitors as respiratory drugs for the treatment of COPD.

Market Competition

Examples of some of the market participants in lung disease therapeutics market identified across the value chain include GlasxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, Sanofi, Roche, Teva Pharmaceuticals, Astellas Pharma, Asmacure Ltée, Dr. Reddy’s Laboratories Ltd.

Attributed to the presence of such a high number of participants, the market is highly competitive. While global players such as GlasxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, and Sanofi account for considerable market size, several regional level players are also operating across key growth regions, particularly in the Asia Pacific.

  • In June 2022, AstraZeneca announced that the company’s Imfinzi exhibited positive high-level results in resectable non-small cell lung cancer.
  • In February 2020 – Boehringer Ingelheim announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketing authorization for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults. In September, the U.S. Food and Drug Administration (FDA) approved nintedanib as the first and only medicine to slow the rate of decline in pulmonary function in adults living with SSc-ILD. Regulatory approvals for the treatment of patients living with SSc-ILD have also been granted in other countries including Canada, Japan, and Brazil.

Report Scope

Report Attribute

Details

Growth Rate

CAGR of 6.21% from 2022 to 2032

Expected Market Value (2022)

US$ 79,833.6 Million

Anticipated Forecast Value (2032)

US$ 145,960.2 Million

Base Year for Estimation

2021

Historical Data

2016-2021

Forecast Period

2022-2032

Quantitative Units

Revenue in US$ Million and CAGR from 2022-2032

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Disease Type
  • Treatment Type
  • Distribution Channel
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia
  • New Zealand
  • China
  • Japan
  • South Korea
  • India
  • ASEAN
  • GCC
  • South Africa

Key Companies Profiled

Customization

Available Upon Request

Key Segments Profiled In The Lung Disease Therapeutics Industry Survey

Lung Disease Therapeutics Market by Disease Type:

  • Lung Disease Therapeutics for COPD
  • Lung Disease Therapeutics for Chronic Bronchitis
  • Lung Disease Therapeutics for Emphysema
  • Lung Disease Therapeutics for Bronchopulmonary dysplasia
  • Lung Disease Therapeutics for Pulmonary Fibrosis
  • Lung Disease Therapeutics for Asthma
  • Lung Disease Therapeutics for Other Lung Disease Therapeutics

Lung Disease Therapeutics Market by Treatment Type:

  • Lung Disease Therapeutic through Drugs
    • Diuretics
    • Steroids
  • Lung Disease Therapeutics through Bronchodilators
  • Lung Disease Therapeutics through Antibiotics
  • Lung Disease Therapeutics through Anti-inflammatory Agents
  • Lung Disease Therapeutics through Oxygen Therapy
  • Lung Disease Therapeutics through Other Treatment Types

Lung Disease Therapeutics Market by Distribution Channel:

  • Lung Disease Therapeutics across Hospital Pharmacies
  • Lung Disease Therapeutics across Retail Pharmacies
  • Lung Disease Therapeutics across Online Pharmacies and E-commerce
  • Lung Disease Therapeutics across Drugstores
  • Lung Disease Therapeutics across Other Distribution Channels

Lung Disease Therapeutics Market by Region:

  • North America Lung Disease Therapeutics Market
  • Latin America Lung Disease Therapeutics Market
  • Europe Lung Disease Therapeutics Market
  • Asia Pacific Lung Disease Therapeutics Market
  • Middle East & Africa Lung Disease Therapeutics Market

Frequently Asked Questions

FMI projects the global lung disease therapeutics market to expand at a 5.6% value CAGR by 2032

North America is expected to be the most opportunistic with a 35.0% share of the total lung disease therapeutics market

GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, Sanofi, are some prominent lung disease therapeutics market manufacturers.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Lung Disease Therapeutics Market Analysis 2017-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Lung Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Disease Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Disease Type, 2017-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Disease Type, 2022-2032

        5.3.1. COPD

        5.3.2. Chronic Bronchitis

        5.3.3. Emphysema

        5.3.4. Bronchopulmonary Dysplasia

        5.3.5. Pulmonary Fibrosis

        5.3.6. Asthma

        5.3.7. Others

    5.4. Y-o-Y Growth Trend Analysis By Disease Type, 2017-2021

    5.5. Absolute $ Opportunity Analysis By Disease Type, 2022-2032

6. Global Lung Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Treatment Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Treatment Type, 2017-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Treatment Type, 2022-2032

        6.3.1. Drugs

            6.3.1.1. Diuretics

            6.3.1.2. Bronchodilators

            6.3.1.3. Steroids

        6.3.2. Antibiotics

        6.3.3. Anti-inflammatory Agents

        6.3.4. Oxygen Therapy

        6.3.5. Others

    6.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2017-2021

    6.5. Absolute $ Opportunity Analysis By Treatment Type, 2022-2032

7. Global Lung Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021

    7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Online Pharmacies & E-commerce

        7.3.4. Drugstores

        7.3.5. Others

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021

    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032

8. Global Lung Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021

    8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Lung Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        9.2.1. By Country

            9.2.1.1. US

            9.2.1.2. Canada

        9.2.2. By Disease Type

        9.2.3. By Treatment Type

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Disease Type

        9.3.3. By Treatment Type

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Lung Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Disease Type

        10.2.3. By Treatment Type

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Disease Type

        10.3.3. By Treatment Type

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Europe Lung Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. U.K.

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Disease Type

        11.2.3. By Treatment Type

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Disease Type

        11.3.3. By Treatment Type

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. Asia Pacific Lung Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

            12.2.1.4. Rest of Asia Pacific

        12.2.2. By Disease Type

        12.2.3. By Treatment Type

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Disease Type

        12.3.3. By Treatment Type

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. MEA Lung Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of MEA

        13.2.2. By Disease Type

        13.2.3. By Treatment Type

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Disease Type

        13.3.3. By Treatment Type

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. Key Countries Lung Disease Therapeutics Market Analysis

    14.1. US

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2021

            14.1.2.1. By Disease Type

            14.1.2.2. By Treatment Type

            14.1.2.3. By Distribution Channel

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2021

            14.2.2.1. By Disease Type

            14.2.2.2. By Treatment Type

            14.2.2.3. By Distribution Channel

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2021

            14.3.2.1. By Disease Type

            14.3.2.2. By Treatment Type

            14.3.2.3. By Distribution Channel

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2021

            14.4.2.1. By Disease Type

            14.4.2.2. By Treatment Type

            14.4.2.3. By Distribution Channel

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2021

            14.5.2.1. By Disease Type

            14.5.2.2. By Treatment Type

            14.5.2.3. By Distribution Channel

    14.6. U.K.

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2021

            14.6.2.1. By Disease Type

            14.6.2.2. By Treatment Type

            14.6.2.3. By Distribution Channel

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2021

            14.7.2.1. By Disease Type

            14.7.2.2. By Treatment Type

            14.7.2.3. By Distribution Channel

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2021

            14.8.2.1. By Disease Type

            14.8.2.2. By Treatment Type

            14.8.2.3. By Distribution Channel

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2021

            14.9.2.1. By Disease Type

            14.9.2.2. By Treatment Type

            14.9.2.3. By Distribution Channel

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2021

            14.10.2.1. By Disease Type

            14.10.2.2. By Treatment Type

            14.10.2.3. By Distribution Channel

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2021

            14.11.2.1. By Disease Type

            14.11.2.2. By Treatment Type

            14.11.2.3. By Distribution Channel

    14.12. South Korea

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2021

            14.12.2.1. By Disease Type

            14.12.2.2. By Treatment Type

            14.12.2.3. By Distribution Channel

    14.13. GCC Countries

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2021

            14.13.2.1. By Disease Type

            14.13.2.2. By Treatment Type

            14.13.2.3. By Distribution Channel

    14.14. South Africa

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2021

            14.14.2.1. By Disease Type

            14.14.2.2. By Treatment Type

            14.14.2.3. By Distribution Channel

    14.15. Israel

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2021

            14.15.2.1. By Disease Type

            14.15.2.2. By Treatment Type

            14.15.2.3. By Distribution Channel

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Disease Type

        15.3.3. By Treatment Type

        15.3.4. By Distribution Channel

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. GlasxoSmithKline

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. Boehringer Ingelheim

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. AstraZeneca

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. Novartis

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Sanofi

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Roche

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. Teva Pharmaceuticals

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. Astellas Pharma

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. Odan Laboratories

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. Dr. Reddy’s Laboratories Ltd

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

        16.1.11. Eli Lilly and Company

            16.1.11.1. Overview

            16.1.11.2. Product Portfolio

            16.1.11.3. Profitability by Market Segments

            16.1.11.4. Sales Footprint

            16.1.11.5. Strategy Overview

                16.1.11.5.1. Marketing Strategy

        16.1.12. Pfizer Inc.

            16.1.12.1. Overview

            16.1.12.2. Product Portfolio

            16.1.12.3. Profitability by Market Segments

            16.1.12.4. Sales Footprint

            16.1.12.5. Strategy Overview

                16.1.12.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Region, 2017-2032

Table 2: Global Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Disease Type, 2017-2032

Table 3: Global Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Treatment Type, 2017-2032

Table 4: Global Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 5: North America Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 6: North America Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Disease Type, 2017-2032

Table 7: North America Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Treatment Type, 2017-2032

Table 8: North America Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 9: Latin America Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 10: Latin America Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Disease Type, 2017-2032

Table 11: Latin America Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Treatment Type, 2017-2032

Table 12: Latin America Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 13: Europe Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 14: Europe Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Disease Type, 2017-2032

Table 15: Europe Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Treatment Type, 2017-2032

Table 16: Europe Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 17: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 18: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Disease Type, 2017-2032

Table 19: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Treatment Type, 2017-2032

Table 20: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 21: MEA Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 22: MEA Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Disease Type, 2017-2032

Table 23: MEA Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Treatment Type, 2017-2032

Table 24: MEA Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Lung Disease Therapeutics Market Value (US$ Mn) by Disease Type, 2022-2032

Figure 2: Global Lung Disease Therapeutics Market Value (US$ Mn) by Treatment Type, 2022-2032

Figure 3: Global Lung Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 4: Global Lung Disease Therapeutics Market Value (US$ Mn) by Region, 2022-2032

Figure 5: Global Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Region, 2017-2032

Figure 6: Global Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 7: Global Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 8: Global Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Disease Type, 2017-2032

Figure 9: Global Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032

Figure 10: Global Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032

Figure 11: Global Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Treatment Type, 2017-2032

Figure 12: Global Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Treatment Type, 2022-2032

Figure 13: Global Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Treatment Type, 2022-2032

Figure 14: Global Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 15: Global Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 16: Global Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 17: Global Lung Disease Therapeutics Market Attractiveness by Disease Type, 2022-2032

Figure 18: Global Lung Disease Therapeutics Market Attractiveness by Treatment Type, 2022-2032

Figure 19: Global Lung Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032

Figure 20: Global Lung Disease Therapeutics Market Attractiveness by Region, 2022-2032

Figure 21: North America Lung Disease Therapeutics Market Value (US$ Mn) by Disease Type, 2022-2032

Figure 22: North America Lung Disease Therapeutics Market Value (US$ Mn) by Treatment Type, 2022-2032

Figure 23: North America Lung Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 24: North America Lung Disease Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 25: North America Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 26: North America Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 27: North America Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 28: North America Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Disease Type, 2017-2032

Figure 29: North America Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032

Figure 30: North America Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032

Figure 31: North America Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Treatment Type, 2017-2032

Figure 32: North America Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Treatment Type, 2022-2032

Figure 33: North America Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Treatment Type, 2022-2032

Figure 34: North America Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 35: North America Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 36: North America Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 37: North America Lung Disease Therapeutics Market Attractiveness by Disease Type, 2022-2032

Figure 38: North America Lung Disease Therapeutics Market Attractiveness by Treatment Type, 2022-2032

Figure 39: North America Lung Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032

Figure 40: North America Lung Disease Therapeutics Market Attractiveness by Country, 2022-2032

Figure 41: Latin America Lung Disease Therapeutics Market Value (US$ Mn) by Disease Type, 2022-2032

Figure 42: Latin America Lung Disease Therapeutics Market Value (US$ Mn) by Treatment Type, 2022-2032

Figure 43: Latin America Lung Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 44: Latin America Lung Disease Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 45: Latin America Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 46: Latin America Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 47: Latin America Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 48: Latin America Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Disease Type, 2017-2032

Figure 49: Latin America Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032

Figure 50: Latin America Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032

Figure 51: Latin America Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Treatment Type, 2017-2032

Figure 52: Latin America Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Treatment Type, 2022-2032

Figure 53: Latin America Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Treatment Type, 2022-2032

Figure 54: Latin America Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 55: Latin America Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 56: Latin America Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 57: Latin America Lung Disease Therapeutics Market Attractiveness by Disease Type, 2022-2032

Figure 58: Latin America Lung Disease Therapeutics Market Attractiveness by Treatment Type, 2022-2032

Figure 59: Latin America Lung Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032

Figure 60: Latin America Lung Disease Therapeutics Market Attractiveness by Country, 2022-2032

Figure 61: Europe Lung Disease Therapeutics Market Value (US$ Mn) by Disease Type, 2022-2032

Figure 62: Europe Lung Disease Therapeutics Market Value (US$ Mn) by Treatment Type, 2022-2032

Figure 63: Europe Lung Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 64: Europe Lung Disease Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 65: Europe Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 66: Europe Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 67: Europe Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 68: Europe Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Disease Type, 2017-2032

Figure 69: Europe Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032

Figure 70: Europe Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032

Figure 71: Europe Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Treatment Type, 2017-2032

Figure 72: Europe Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Treatment Type, 2022-2032

Figure 73: Europe Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Treatment Type, 2022-2032

Figure 74: Europe Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 75: Europe Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 76: Europe Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 77: Europe Lung Disease Therapeutics Market Attractiveness by Disease Type, 2022-2032

Figure 78: Europe Lung Disease Therapeutics Market Attractiveness by Treatment Type, 2022-2032

Figure 79: Europe Lung Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032

Figure 80: Europe Lung Disease Therapeutics Market Attractiveness by Country, 2022-2032

Figure 81: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) by Disease Type, 2022-2032

Figure 82: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) by Treatment Type, 2022-2032

Figure 83: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 84: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 85: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 86: Asia Pacific Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 87: Asia Pacific Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 88: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Disease Type, 2017-2032

Figure 89: Asia Pacific Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032

Figure 90: Asia Pacific Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032

Figure 91: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Treatment Type, 2017-2032

Figure 92: Asia Pacific Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Treatment Type, 2022-2032

Figure 93: Asia Pacific Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Treatment Type, 2022-2032

Figure 94: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 95: Asia Pacific Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 96: Asia Pacific Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 97: Asia Pacific Lung Disease Therapeutics Market Attractiveness by Disease Type, 2022-2032

Figure 98: Asia Pacific Lung Disease Therapeutics Market Attractiveness by Treatment Type, 2022-2032

Figure 99: Asia Pacific Lung Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032

Figure 100: Asia Pacific Lung Disease Therapeutics Market Attractiveness by Country, 2022-2032

Figure 101: MEA Lung Disease Therapeutics Market Value (US$ Mn) by Disease Type, 2022-2032

Figure 102: MEA Lung Disease Therapeutics Market Value (US$ Mn) by Treatment Type, 2022-2032

Figure 103: MEA Lung Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 104: MEA Lung Disease Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 105: MEA Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 106: MEA Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 107: MEA Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 108: MEA Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Disease Type, 2017-2032

Figure 109: MEA Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032

Figure 110: MEA Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032

Figure 111: MEA Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Treatment Type, 2017-2032

Figure 112: MEA Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Treatment Type, 2022-2032

Figure 113: MEA Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Treatment Type, 2022-2032

Figure 114: MEA Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 115: MEA Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 116: MEA Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 117: MEA Lung Disease Therapeutics Market Attractiveness by Disease Type, 2022-2032

Figure 118: MEA Lung Disease Therapeutics Market Attractiveness by Treatment Type, 2022-2032

Figure 119: MEA Lung Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032

Figure 120: MEA Lung Disease Therapeutics Market Attractiveness by Country, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Chronic Disease Management Market

Published : November 2017

Healthcare

Airway Disease Treatment Market

Published : March 2017

Healthcare

Lung Cancer Therapeutics Market

Published : February 2022

Healthcare

Lung Cancer Surgery Market

Published : January 2022

Google translate

Lung Disease Therapeutics Market